Are RA patients from a non-endemic HCV population screened for HCV? A cross-sectional analysis of three different settings

Reumatol Clin. 2017 May-Jun;13(3):156-159. doi: 10.1016/j.reuma.2016.03.006. Epub 2016 Apr 29.
[Article in English, Spanish]

Abstract

Introduction: In Mexico, other risk factors are associated with hepatitis C virus (HCV): prior heroin users, living alone, widower, and northern region residence. Rheumatoid arthritis (RA) patients are considered immunosuppressed and HCV testing is recommended before treatment. The aim of the study was to describe the characteristics of HCV testing in RA patients in three different medical care settings in a non-endemic area.

Methods: A retrospective observational study was performed using medical records from 960 RA patients describing the indications for HCV testing.

Results: The test was performed in 28.6% and the HCV overall frequency was 0.36%. Population characteristics were not associated with an increased risk of HCV infection; therefore, anti-HCV positivity was low. The main reason for testing was before starting biological agents.

Conclusion: Due to the low pre-test probability, testing for HCV infection should be personalized; i.e., according to disease prevalence in a particular geographical location and the individual risk factors.

Keywords: Artritis reumatoide; Factores de riesgo; Hepatitis C virus; Prueba de laboratorio; Rheumatoid arthritis; Risk factors; Testing; Virus de hepatitis C.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Aged
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid / drug therapy
  • Arthritis, Rheumatoid / immunology
  • Arthritis, Rheumatoid / virology*
  • Cross-Sectional Studies
  • Female
  • Guideline Adherence / statistics & numerical data*
  • Hepatitis C / complications
  • Hepatitis C / diagnosis*
  • Hepatitis C / epidemiology
  • Humans
  • Male
  • Mexico
  • Middle Aged
  • Practice Guidelines as Topic
  • Practice Patterns, Physicians' / statistics & numerical data*
  • Prevalence
  • Retrospective Studies
  • Risk Factors

Substances

  • Antirheumatic Agents